HES1 and neoplasm: Although there was a significant inhibition of the pharmacodynamic marker HES1 post-treatment with MK0752, no noticeable change was observed in tumor morphology, tumor cell proliferation and induction of apoptosis between the control and treatment arms (Fig. 4A).